2024

Gupta, S. D. et al. (2024) Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.3515) (PMID:39563094) (Early Online Publication)

Butt, J. H., Shen, L., Inzucchi, S. E., Docherty, K. F. , Jhund, P. S. , Martinez, F. A., Sabatine, M. S., Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2024) Dapagliflozin in heart failure, type 2 diabetes, and neuropathy. JACC: Heart Failure, 12(11), pp. 1946-1948. (doi: 10.1016/j.jchf.2024.07.017) (PMID:39269393)

Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12(9), pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262)

Butt, J. H. et al. (2024) Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: Comprehensive individual participant-level analysis of 6 randomized clinical trials. Circulation, (doi: 10.1161/circulationaha.124.071110) (PMID:39217458) (Accepted for Publication)

Butt, J. H. et al. (2024) Anthropometric measures and long‐term mortality in non‐ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox. European Journal of Heart Failure, (doi: 10.1002/ejhf.3424) (PMID:39155576) (Early Online Publication)

Butt, J. H. et al. (2024) Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER. Journal of Cardiac Failure, 30(3), pp. 436-448. (doi: 10.1016/j.cardfail.2023.08.027) (PMID:38104937)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Vart, P. et al. (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 79(2), glad181. (doi: 10.1093/gerona/glad181) (PMID:37527836) (PMCID:PMC10809037)

2023

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)

Butt, J. et al. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)

Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 25(10), pp. 1831-1839. (doi: 10.1002/ejhf.2944) (PMID:37369637) (PMCID:PMC10947165)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, 25(9), pp. 1606-1618. (doi: 10.1002/ejhf.2962) (PMID:37401511)

Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)

Butt, J. H. et al. (2023) Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial. European Journal of Heart Failure, 25(8), pp. 1228-1242. (doi: 10.1002/ejhf.2851) (PMID:37042062)

Araki, T. et al. (2023) Relationship between the volume of cases and in-hospital mortality in patients with cardiogenic shock receiving short-term mechanical circulatory support. American Heart Journal, 261, pp. 109-123. (doi: 10.1016/j.ahj.2023.03.017) (PMID:37031832)

Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)

Jhund, P. S. et al. (2023) Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER trial. JAMA Cardiology, 8(6), pp. 554-563. (doi: 10.1001/jamacardio.2023.0711) (PMID:37099283) (PMCID:PMC10134044)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Butt, J. H., Solomon, S. D. and McMurray, J. J.V. (2023) Response by Butt et al to letter regarding article, “Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial”. Circulation, 147(14), pp. 1119-1120. (doi: 10.1161/CIRCULATIONAHA.123.064052) (PMID:37011075)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)

Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)

Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)

Butt, J. H. et al. (2023) Urinary cGMP (cyclic guanosine monophosphate)/BNP (B-type natriuretic peptide) ratio, sacubitril/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial. Circulation: Heart Failure, 16(3), pp. 247-258. (doi: 10.1161/CIRCHEARTFAILURE.122.010111) (PMID:36943907) (PMCID:PMC10022671)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Johansen, N. D. et al. (2023) A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: a nationwide cohort study. Circulation: Heart Failure, 16(2), e009729. (doi: 10.1161/CIRCHEARTFAILURE.122.009729) (PMID:36809039)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

2022

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)

Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)

Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation, 146(16), pp. 1210-1224. (doi: 10.1161/CIRCULATIONAHA.122.061754) (PMID:36029465) (PMCID:PMC9815819)

Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)

Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)

Butt, J. H. and McMurray, J. J.V. (2022) Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. European Journal of Heart Failure, 24(9), pp. 1623-1624. (doi: 10.1002/ejhf.2647) (PMID:35919944)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Zahir, D. et al. (2022) Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017. European Journal of Heart Failure, 24(3), pp. 539-547. (doi: 10.1002/ejhf.2418) (PMID:34969178)

2021

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Articles

Gupta, S. D. et al. (2024) Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.3515) (PMID:39563094) (Early Online Publication)

Butt, J. H., Shen, L., Inzucchi, S. E., Docherty, K. F. , Jhund, P. S. , Martinez, F. A., Sabatine, M. S., Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2024) Dapagliflozin in heart failure, type 2 diabetes, and neuropathy. JACC: Heart Failure, 12(11), pp. 1946-1948. (doi: 10.1016/j.jchf.2024.07.017) (PMID:39269393)

Butt, J. et al. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12(9), pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018) (PMID:38573262)

Butt, J. H. et al. (2024) Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: Comprehensive individual participant-level analysis of 6 randomized clinical trials. Circulation, (doi: 10.1161/circulationaha.124.071110) (PMID:39217458) (Accepted for Publication)

Butt, J. H. et al. (2024) Anthropometric measures and long‐term mortality in non‐ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox. European Journal of Heart Failure, (doi: 10.1002/ejhf.3424) (PMID:39155576) (Early Online Publication)

Butt, J. H. et al. (2024) Heart failure, investigator-reported sleep apnea and dapagliflozin: A patient-level pooled meta-analysis of DAPA-HF and DELIVER. Journal of Cardiac Failure, 30(3), pp. 436-448. (doi: 10.1016/j.cardfail.2023.08.027) (PMID:38104937)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Vart, P. et al. (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 79(2), glad181. (doi: 10.1093/gerona/glad181) (PMID:37527836) (PMCID:PMC10809037)

Kondo, T. et al. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16(12), e010898. (doi: 10.1161/CIRCHEARTFAILURE.123.010898) (PMID:37886880)

Butt, J. H. et al. (2023) Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER. European Journal of Heart Failure, 25(11), pp. 2078-2090. (doi: 10.1002/ejhf.3000) (PMID:37634087)

Butt, J. et al. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11(10), pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016) (PMID:37318419)

Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 25(10), pp. 1831-1839. (doi: 10.1002/ejhf.2944) (PMID:37369637) (PMCID:PMC10947165)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, 25(9), pp. 1606-1618. (doi: 10.1002/ejhf.2962) (PMID:37401511)

Yang, M. et al. (2023) Stroke in patients with heart failure and reduced or preserved ejection fraction. European Heart Journal, 44(31), pp. 2998-3013. (doi: 10.1093/eurheartj/ehad338) (PMID:37358785) (PMCID:PMC10424882)

Butt, J. H. et al. (2023) Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial. European Journal of Heart Failure, 25(8), pp. 1228-1242. (doi: 10.1002/ejhf.2851) (PMID:37042062)

Araki, T. et al. (2023) Relationship between the volume of cases and in-hospital mortality in patients with cardiogenic shock receiving short-term mechanical circulatory support. American Heart Journal, 261, pp. 109-123. (doi: 10.1016/j.ahj.2023.03.017) (PMID:37031832)

Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)

Tolomeo, P. et al. (2023) Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. European Heart Journal, 44(24), pp. 2202-2212. (doi: 10.1093/eurheartj/ehad210) (PMID:37051752)

Jhund, P. S. et al. (2023) Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER trial. JAMA Cardiology, 8(6), pp. 554-563. (doi: 10.1001/jamacardio.2023.0711) (PMID:37099283) (PMCID:PMC10134044)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Butt, J. H., Solomon, S. D. and McMurray, J. J.V. (2023) Response by Butt et al to letter regarding article, “Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial”. Circulation, 147(14), pp. 1119-1120. (doi: 10.1161/CIRCULATIONAHA.123.064052) (PMID:37011075)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)

Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)

Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)

Butt, J. H. et al. (2023) Urinary cGMP (cyclic guanosine monophosphate)/BNP (B-type natriuretic peptide) ratio, sacubitril/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial. Circulation: Heart Failure, 16(3), pp. 247-258. (doi: 10.1161/CIRCHEARTFAILURE.122.010111) (PMID:36943907) (PMCID:PMC10022671)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Johansen, N. D. et al. (2023) A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: a nationwide cohort study. Circulation: Heart Failure, 16(2), e009729. (doi: 10.1161/CIRCHEARTFAILURE.122.009729) (PMID:36809039)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)

Butt, J. H. et al. (2022) Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in DELIVER. Journal of the American College of Cardiology, 80(18), pp. 1705-1717. (doi: 10.1016/j.jacc.2022.08.718) (PMID:36041668)

Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)

Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER trial. Circulation, 146(16), pp. 1210-1224. (doi: 10.1161/CIRCULATIONAHA.122.061754) (PMID:36029465) (PMCID:PMC9815819)

Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)

Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)

Butt, J. H. and McMurray, J. J.V. (2022) Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. European Journal of Heart Failure, 24(9), pp. 1623-1624. (doi: 10.1002/ejhf.2647) (PMID:35919944)

Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Zahir, D. et al. (2022) Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003–2017. European Journal of Heart Failure, 24(3), pp. 539-547. (doi: 10.1002/ejhf.2418) (PMID:34969178)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)